Monthly Archives

January 2021

Veralox Therapeutics Announces IND Submission for VLX-1005 to Treat Heparin-Inducted Thrombocytopenia

By | News | No Comments

FREDERICK, Md – January [XX], 2021 – Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced it submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for initiation of a Phase 1 clinical trial of VLX-1005, a first-in-class small molecule inhibitor of 12-Lipoxygenase in development for the treatment of heparin-induced thrombocytopenia (HIT).

HIT is an immune complication of heparin therapy resulting in low platelet counts caused by antibodies to complexes of platelet factor 4 (PF4) and heparin. Currently, one third of hospitalized patients in the U.S., or about 12 million a year, receive heparin. HIT is the most important and most frequent drug‐induced type of thrombocytopenia.

“This IND submission is a key milestone for Veralox and a tribute to the hard work and dedication of our team to advance VLX-1005 to first in human studies,” said Jeffrey Strovel, Ph.D., Chief Executive Officer of Veralox Therapeutics, Inc.
“We are excited to continue our efforts to further develop this groundbreaking new therapy for patients suffering from HIT,” David Maloney, Ph.D., Chief Scientific Officer of Veralox Therapeutics.

About VLX-1005

VLX-1005 is a first-in-class and selective small molecule inhibitor 12-Lipoxygenase, a key target within the arachidonic acid pathway. Preclinical data has demonstrated that VLX-1005 halts immune driven platelet activation and thrombosis thus offering the potential of a lifesaving treatment for patients with HIT.

About Veralox Therapeutics

VERALOX Therapeutics Inc. (Veralox Website) is developing first-in-class therapeutics that target the underlying pathologies of diseases with unmet medical needs. The company’s lead candidate, VLX-1005, will be developed initially to treat patients with heparin-induced thrombocytopenia (HIT). Second generation therapeutic products are under development for T1D and other immune-mediated and inflammatory diseases.

Contact:
Jeffrey Strovel, CEO
Jeff@veralox.com

Myeloid Therapeutics and MaxCyte Enter Clinical and Commercial Licensing Agreement to Advance Myeloid’s Cell Therapy Programs

By | News | No Comments

Myeloid to utilize MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to advance its novel cell therapies to treat solid tumors, T cell lymphoma and glioblastoma

CAMBRIDGE, MA and GAITHERSBURG, MD, January 11, 2021 — Myeloid Therapeutics, Inc., a company harnessing and reprogramming myeloid cells to treat cancers, and MaxCyte, Inc., a global cell-based therapies and life sciences company, today announce the signing of a clinical and commercial licensing agreement.

Myeloid Therapeutics will obtain non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform. This agreement enables Myeloid to advance its pipeline programs, including for engineered cell therapies targeting solid tumors, T cell lymphoma, and glioblastoma. In return, MaxCyte is entitled to receive undisclosed development and approval milestones, and sales-based payments, along with other licensing fees.

Myeloid’s ATAK™ platform leverages the unique power of myeloid cells to help patients fighting cancers that, until now, have been very difficult to treat. By targeting myeloid cells, the technology allows for diverse applications and Myeloid’s pipeline expansion is ongoing.

“We are very excited to be working with MaxCyte, an established leader in cell engineering. This agreement provides long-term access to MaxCyte’s unique electroporation technology platform, representing an important enabling step in the continued clinical advancement of targeted cell-based therapies, for patients with few if no options,” said Daniel Getts, PhD, CEO of Myeloid. “The ease of use and integration of MaxCyte instruments into our workflow allows us to envision rapid-same-day turnaround of cell treatments for patients presenting with aggressive tumors.”

Doug Doerfler, President & CEO of MaxCyte, said: “We are proud to support Myeloid’s work and are excited about the company’s novel approach to engineering and harnessing the innate capabilities of the myeloid cell. This agreement represents an important achievement for MaxCyte as it expands the use of our next-generation technology platform to support engineering in novel cell types. Myeloid’s ATAK™ technology is being developed for several critical applications in cancer.”

MaxCyte’s ExPERT instrument portfolio represents the next generation of leading, clinically validated, electroporation technology for complex and scalable cell engineering. By delivering high transfection efficiency, seamless scalability and enhanced functionality, the ExPERT platform delivers the high-end performance essential to enable the next wave of biological and cellular therapeutics.

About Myeloid Therapeutics

Myeloid Therapeutics is an immunology company focused on combining immunologic insights with cutting-edge technologies to harness myeloid cells to eradicate cancer and other diseases. The Company’s ATAKTM platform technology can be broadly applied, and it is initially advancing a cell therapy program for T cell lymphoma and a primed monocyte approach to treat glioblastoma. The ATAK platform is scalable to multiple treatment modalities and other disease areas in collaboration with partners. Myeloid expects to enter the clinic with its two lead programs in the first half of 2021. For more information, visit visit www.myeloidtx.com.

About MaxCyte

MaxCyte is a clinical-stage global cell-based therapies and life sciences company. As the inventors of the premier cell-engineering enabling technology, the Company helps bring the promise of next-generation cell and gene-editing therapies to life. The Company’s technology is currently being deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licenses have been granted for more than 120 cell therapy programs, with more than 90 licensed for clinical use, and the Company has now entered into twelve clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998 and is headquartered in Gaithersburg, Maryland, US. For more information, visit www.maxcyte.com

Myeloid Media Contact
Sarah Sutton
Glover Park Group
ssutton@gpg.com
+1 202-741-1990

MaxCyte Contacts:

MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Amanda Murphy, Chief Financial Officer
+1 301-944-1660  

US Media Relations
Jamie Lacey-Moreira
+1 410-299-3310
jamielacey@presscommpr.com

Chris Mathia, Chief Executive Officer, Innara Health, and Keith Molzer, Managing Partner, Flyover Capital, join Rich Bendis from Kansas City on BioTalk

By | BioTalk, News | No Comments

While home in Kansas City for the season, BioTalk host Rich Bendis virtually sits down two local business leaders. Innar Health CEO, Chris Mathia, and Flyover Capital Managing Partner, Keith Molzer chat about the opportunities and challenges of BioHealth and Fund-Raising in Middle American.

Listen now via Google http://bit.ly/39ikNss, Apple http://apple.co/3shRRtk, Spotify http://spoti.fi/39ocgUz, and TuneIn http://bit.ly/2XvT0za.

A Kansas City, Kansas native, Chris Mathia joined Innara Health as Vice President of Sales in October of 2017. He was promoted to Chief Executive Officer in May of 2019 and brings 20+ years of healthcare sales and leadership experience to the Innara team. Throughout his career, he has focused on building client confidence, improving the client experience, and increasing overall client satisfaction and reference ability.

Prior to joining Innara, Chris served in various sales and leadership roles with Perceptive/Hyland Software, Cerner Corporation, Thompson Reuters, and Medline Industries. Chris received his bachelor’s degree in Political Science from the University of Kansas.

From working on his grandparent’s farm in Nebraska to becoming a serial entrepreneur, getting his hands dirty is in Keith’s DNA.   Keith has been an entrepreneur for more than 35 years, starting a variety of companies in the Kansas City region.

Prior to co-founding Flyover Capital in 2014, Keith Molzer founded Balance Innovations in 2004 and built the company into the leading developer of cash office software solutions for the retail industry (acquired by Brinks). Prior to founding Balance Innovations, Keith founded in worked with several other start-ups including Entrepreneurial Consulting Corporation which advised clients within technology, economic development agencies, state, and federal government agencies. Clients included the Kauffman Foundation, KTEC, NIST/ATP, KCCatalyst, and several state entrepreneurial initiatives.

Keith has a passion for supporting entrepreneurship and has spoken as a guest lecturer at Rockhurst University, University of Nebraska, the University of Kansas. Keith has also served as a mentor for KCSpark Lab, KC Pipeline, and the KC Tech Counsel.  Outside of Flyover, Keith is also an active angel investor and has invested in over 15 deals throughout the Midwest. Keith currently serves on the boards of Lending Standard, Innara Health, Inprentus, Verusen, Aker and Layr.  He previously served on the boards of Agrible (acquired by Nutrien), Risk Genius (Acquired by Bold Penguin), and Balance Innovations (acquired by Brinks).

Click here for the transcript.

Join our Mailing List